Disc Medicine (IRON) Cash from Investing Activities (2020 - 2026)
Disc Medicine (IRON) posted quarterly Cash from Investing Activities of $21.6 million for Q2 2026, down 58.16% year-over-year from $51.7 million in Q2 2025, and down 62.9% quarter-over-quarter from $58.3 million in Q1 2026.
Powered by 
Analysis
Disc Medicine (IRON) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Cash from Investing Activities for 7 consecutive years, with $21.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 58.16% year-over-year to $21.6 million; the TTM figure through Jun 2026 stood at -$93.4 million (up 68.17% YoY), while the FY2025 annual figure was -$394.3 million, down 34.88% from the prior year.
- Cash from Investing Activities retreated to $21.6 million in Q2 2026 per IRON's latest filing, from $58.3 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $58.3 million in Q1 2026 and bottomed at -$272.6 million in Q1 2025.
- Historically, Cash from Investing Activities has averaged -$33.7 million across 5 years, with a median of -$24500.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 1831141.67% — and 2025, when it soared 169.68%.
- Disc Medicine's Cash from Investing Activities stood at -$12000.0 in 2022, then jumped by 75.0% to -$3000.0 in 2023, then tumbled by 47433.33% to -$1.4 million in 2024, then tumbled by 15530.65% to -$222.9 million in 2025, then soared by 109.7% to $21.6 million in 2026.
- Business Quant data shows IRON's Cash from Investing Activities at $21.6 million in Q2 2026, $58.3 million in Q1 2026, and -$222.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | 21.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.63 Mn |
| Mar 31, 2026 | 58.31 Mn |
| Dec 31, 2025 | -222.89 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Jun 30, 2025 | 51.69 Mn |
| Mar 31, 2025 | -272.63 Mn |
| Dec 31, 2024 | -1.43 Mn |
| Sep 30, 2024 | -71.09 Mn |
| Jun 30, 2024 | -219.75 Mn |
| Mar 31, 2024 | -67,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | -12,000.00 |
| Mar 31, 2023 | -29,000.00 |
| Dec 31, 2022 | -12,000.00 |
| Sep 30, 2022 | -19,000.00 |
| Jun 30, 2022 | -20,000.00 |
| Mar 31, 2022 | -100,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Dec 31, 2020 | -120.75 Mn |